One-Year Outcomes of 1 Dose versus 3 Loading Doses Followed by Pro Re Nata Regimen Using Ranibizumab for Neovascular Age-Related Macular Degeneration: The ARTIS Trial

<div>Time course of central retinal thickness (CRT) on optical coherence tomography. LD group: 3 loading doses followed by the pro re nata regimen (3 + PRN); PRN group: 1 dose followed by the PRN regimen (1 + PRN); M: month.</div>

Journal of Ophthalmology

fig2

Figure 2

Figure 2: One-Year Outcomes of 1 Dose versus 3 Loading Doses Followed by Pro Re Nata Regimen Using Ranibizumab for Neovascular Age-Related Macular Degeneration: The ARTIS Trial 

Figure 2 | One-Year Outcomes of 1 Dose versus 3 Loading Doses Followed by Pro Re Nata Regimen Using Ranibizumab for Neovascular Age-Related Macular Degeneration: The ARTIS Trial 